

Introduction to Polygenic Prediction

History, Theory, Methodology & Applications

Jian Zeng

j.zeng@uq.edu.au

Acknowledgement of Country

- The University of Queensland (UQ) acknowledges the Traditional Owners and their custodianship of the lands on which we meet.
- We pay our respects to their Ancestors and their descendants, who continue cultural and spiritual connections to Country.
- We recognise their valuable contributions to Australian and global society.



General Information:

- We are currently located in Building 69



Emergency evacuation point

- Food court and bathrooms are located in Building 63
- If you are experiencing cold/flu symptoms or have had COVID in the last 7 days please ensure you are wearing a mask for the duration of the module



Data Agreement

To maximize your learning experience, we will be working with genuine human genetic data, during this module.

Access to this data requires agreement to the following in to comply with human genetic data ethics regulations

If you haven't done so, please email <ctr-pdg-admin@imb.uq.edu.au> with your name and the below statement to confirm that you agree with the following:

“I agree that access to data is provided for educational purposes only and that I will not make any copy of the data outside the provided computing accounts.”

Learning materials

Instructions to access WiFi/desktop/server:

<https://suave-pillow-de4.notion.site/Instruction-to-Computing-Resources-dcba658c9a584e6d80a443c5d64042d8?pvs=4>

The winter school server is available until **15th July 2024** (2 weeks after the course)


Slides and practical notes for this module:

<https://cnsgenomics.com/data/teaching/GNGWS24/module5/>

- Understand what polygenic scores (PGS) are [Lecture 1]
- How to evaluate PGS prediction accuracy [Lecture/Prac 2]
- Learn the basic and advanced methods to calculate PGS
 - Basic method [Lecture/Prac 1]
 - Best linear unbiased prediction [Lecture/Prac 3]
 - Bayesian methods [Lecture/Prac 4]
 - Summary-data-based methods [Lecture/Prac 5]
- Our pipeline how to generate a PGS from start to end [Lecture/Prac 6]

Approx. 40 min Lecture | 5 min break | 40 min Prac | 5 min break

Jian Zeng



Tian Lin




Valentin Hivert Fleur Garton

Polygenic scores (PGS)

Polygenic scores (PGS) predict individual genetic values of complex traits using genome variations.

Polygenic risk scores (PRS) are predictors of the genetic susceptibilities of individuals to diseases.



Head in the clouds

Head in the sand

Source: Strachan & Read Human Molecular Genetics 3.

GENETICS | HIGHLIGHTED ARTICLE
GENOMIC PREDICTION

GENOMIC PREDICTION

2019

Complex Trait Prediction from Genome Data: Contrasting EBV in Livestock to PRS in Humans

Naomi R. Wray,^{*,†,1} Kathryn E. Kemper,^{*} Benjamin J. Hayes,[‡] Michael E. Goddard,^{§,***}
and Peter M. Visscher^{*,†}



Shai Carmi @ShaiCarmi · Apr 6

Remember when the Broad Institute discovered polygenic scores? Now it seems as if they invented quantitative genetics.

See below for a thread. (Happy if someone could send me the full text.)

1/7




Concordance of a High Polygenic Score Among Relatives

ahajournals.org


A brief history of PGS in humans & agriculture

Methodology



Application

- **PRS**- Polygenic risk score
- **GPRS**- Genomic or genetic profile risk score
- **PGS** -Polygenic score
- **GRS** - Genetic risk score
- **rsPS** – restricted to significant polygenic score
- **gePS** – global extended polygenic score
- **Multi-SNP score** (usually this uses only single nucleotide polymorphisms (SNPs) that are genome-wide significant, hence the same as gePS)
- **MetaGRS** – a PRS constructed from genetic data for the disease/trait of interest plus from other correlated traits
- **MTAG-GRS/PRS** a PRS constructed from GWAS data from multiple correlated traits
- **Genetic score**
- **Genotypic score**
- **Allele score**
- **Profile score**
- **Linear predictor** (this of course is a generic term, but has been used to describe PRS when risk alleles are the only predictors)



Theory and methodology
of polygenic scores (PGS)
are built on
our understanding of
“polygenicity”
in complex traits.



Height




Schizophrenia



Obesity

Common diseases are polygenic



248 risk loci identified at genome-wide significance level.

We predict thousands are associated with schizophrenia.

nature

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [articles](#) > [article](#)

Article | [Published: 08 April 2022](#)

Mapping genomic loci implicates genes and synaptic biology in schizophrenia

[Vassily Trubetskov](#), [Antonio F. Pardiñas](#), [Ting Qi](#), [Georgia Panagiotaropoulou](#), [Swapnil Awasthi](#), [Tim B. Bigdeli](#), [Julien Bryois](#), [Chia-Yen Chen](#), [Charlotte A. Dennison](#), [Lynsey S. Hall](#), [Max Lam](#), [Kyoko Watanabe](#), [Oleksandr Frei](#), [Tian Ge](#), [Janet C. Harwood](#), [Frank Koopmans](#), [Sigurdur Magnusson](#), [Alexander L. Richards](#), [Julia Sidorenko](#), [Yang Wu](#), [Jian Zeng](#), [Jakob Grove](#), [Minsoo Kim](#), [Zhiqiang Li](#), [Indonesia Schizophrenia Consortium](#), [PsychENCODE](#), [Psychosis Endophenotypes International Consortium](#), [The SynGO Consortium](#), [Schizophrenia Working Group of the Psychiatric Genomics Consortium](#)



[+ Show authors](#)

[Nature](#) **604**, 502–508 (2022) | [Cite this article](#)


57k Accesses | **321** Citations | **463** Altmetric | [Metrics](#)




Common diseases are polygenic



2022 PGC Wave 3













2014 PGC Wave 2




2011 PGC Wave 1

Many polygenic genetic architectures



Many DNA variants contribute to genetic risk, and most have very small effects.

Polygenic disease for an individual




900 DNA polymorphic sites

RV = risk variant

Frequency of risk variant at each site: 0.1 (p)

Average person $900 * 2 * 0.1 = 180$ risk variant

Mean +/- 3SD: 142 to 218




Count of RV in population

- 0 Grey: Homozygote no risk alleles (or equivalently 2 protective alleles)
- 1 Blue : Heterozygote one risk allele (and one non-risk/protective allele)
- 2 Red: Homozygote two risk alleles


Toy
example

Polygenic disease for an individual

Affected over lifetime




Not affected over lifetime



- We all carry risk variants for all diseases.
- Robustness
- Those affected carry a higher burden.
- Non-genetic factors contribute to risk too
- Each person carries a unique portfolio of risk alleles


Polygenic score




→ “True” polygenic score

Genetic variance between people attributed to all genetic factors $V(A)$

$$h^2 = \frac{V(A)}{V(P)} \text{ heritability}$$



Polygenic score



→ "True" polygenic score

Not all variants captured on genotyping arrays

Genetic variance between people attributed to all genetic factors $V(A)$

$$h^2 = \frac{V(A)}{V(P)} \text{ heritability}$$


Genetic variance between people attributed to all genetic factors associated with SNPs on genotyping arrays

$$h_{SNP}^2 = h_g^2 = \frac{V(A:SNP)}{V(P)}$$

SNP – based heritability

Limitations in prediction accuracy

- ❖ PGS have a **theoretical** upper limit dependent on the **heritability of the trait** (how much of the variance of trait values between people is attributed to genetic factors).
- ❖ PGS have a **technical** upper limit associated with the proportion of **variance tagged** by the DNA variants measured.
- ❖ PGS have a **practical** upper limit dependent on the **sample size of the discovery sample** used to estimate effect sizes of risk alleles, and the **quality** of the discovery sample.
- ❖ PGS can be pushed closer to the technical upper limit by the **statistical methodology** used to generate the optimal weighting given to the risk alleles, and new methods integrate new biological data.



Schizophrenia

Max:

25% Liability

AUC 0.84

Current:

11% Liability

AUC 0.74

Polygenic scores cannot be highly accurate predictors of phenotypes

Will people withOUT known family history have high PGS?


Maybe, and that's important!

JAMA Psychiatry | Review

From Basic Science to Clinical Application of Polygenic Risk Scores A Primer


Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD;
Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Not affected over lifetime



Grey: Homozygote: Two non-risk/protective alleles – always passes a non-risk allele to child at the locus
Red: Homozygote: Two risk alleles – always passes a risk allele to child at the locus
Blue: Heterozygotes: One risk allele & one non-risk allele –
passes a risk allele 50% of the time & a non-risk allele 50% of the time

Children (Parents: 171 & 189)



Children of these parents
Mean: 180
+/-3SD: 153-207

Population
Mean: 180
+/-3SD: 142-218

No family history, but by chance segregation of alleles has high genetic risk


Family history

Will people with known family history have high PGS?

Maybe, maybe not!!


JAMA Psychiatry | Review
From Basic Science to Clinical Application of Polygenic Risk Scores
A Primer
Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD; Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Affected over lifetime



Grey: Homozygote: Two non-risk/protective alleles – always passes a non-risk allele to child at the locus
Red: Homozygote: Two risk alleles – always passes a risk allele to child at the locus
Blue: Heterozygotes: One risk allele & one non-risk allele – passes a risk allele 50% of the time & a non-risk allele 50% of the time

Children (Parents: 206 & 180)




Children of these parents
Mean: 193
+/-3SD: 166-220

Population
Mean: 180
+/-3SD: 142-218

- Complex traits are polygenic, with many variants of small effects.
- Prediction accuracy is limited by heritability, SNP set, sample size & statistical method.
- Substantial genetic variation within the family (half of that in the whole population).
- A high PGS is mostly a consequence of genetic sampling.

Evaluations and applications

Polygenic scores



- A weighted count of risk alleles


$$PGS = \widehat{\beta}_1 x_{i1} + \widehat{\beta}_2 x_{i2} + \widehat{\beta}_3 x_{i3} + \dots = \sum_{j=1}^{n_{SNP}} \widehat{\beta}_j x_{ij}$$

0, 1 or 2 Risk alleles

Which SNPs?

What weights?

3. Methods to choose DNA variants and to decide their weights



- Don't need to know causal variants for prediction!
- Prediction can be based on correlated variants.

4. Evaluate PRS in samples with known case-control status

5. Calculate PRS for individuals with unknown disease status and benchmark risk against population

4. Evaluate




$$Y = b \cdot PGS + e$$

$$R^2 = \text{var}(b \cdot PGS) / \text{Var}(Y)$$

AUC statistic:
Probability that a case ranks higher than a control

Accuracy of PRS could be lower when applied in non-European individuals


Different views of the same data



Khera et al (2018) Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics


Torkamani et al, Nat Rev Genetics, 2018

AUC 313-SNPs 0.63



Increase prediction accuracy....

Combine PRS with known risk mutations Breast cancer




BRCA1
carriers

Kuchenbaecker et al: Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2017)

Increase prediction accuracy....

Combine PRS with conventional risk predictors Coronary Artery Disease



Polygenic risk score applications

JAMA Psychiatry | Review

From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD; Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Goal:

- Understandable by interested clinician
- Technically accurate – backed up in Supplement & Rscript



Naomi Wray, UQ & UoOxford



Graham Murray, UoCambridge



Jehannine Austin, UoBritish Columbia









Ian Hickie, UoSydney



John McGrath, UQ



Tian Lin, UQ

Cohort where PRS applied:	<p>Community</p>  <p>Of 100 people in the population, 1 will get "the disease" in lifetime, assuming a disease of lifetime risk of 1%</p>	<p>Symptoms: help-seeking</p>  <p>Of 100 people presenting at clinic with symptoms but without a clear diagnosis, a higher proportion than in a population sample will go on to get "the disease" in their lifetime</p>	<p>Established diagnosis</p>  <p>100 people with diagnosis of "the disease"</p>
Utility of PRS:	<p>PRS contribute to risk stratification</p>  <p>Of 100 people in the top PRS stratum, a higher proportion will get "the disease" in their lifetime and hence are particularly encouraged to enter established disease screening</p>	<p>PRS contribute to clinical decisions</p>  <p>Of 100 people presenting with symptoms AND in the top PRS stratum, a higher proportion than in the clinic-presenting cohort will go on to get diagnosis of "the disease" in their lifetime</p>	<p>PRS contribute to treatment choices</p>  <p>Genetic information may contribute to more effective choice of treatment, with reduced adverse events</p>
Likely applications:	Common diseases/ disorders for which there is already population screening	When there is no clear diagnosis based on presenting symptoms, guide monitoring of emergent symptoms	Potentially all common diseases/disorders but little data available to date
Likely first applications:	Cancers: breast and colorectal; common eye disorders: glaucoma, macular degeneration; heart disease	Differentiating between type 1 and type 2 diabetes	Inflammatory bowel disease is a flagship in the genetics of common disease; perhaps we will see first applications here?

Polygenic risk score applications

JAMA Psychiatry | Review

From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD; Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Goal:

- Understandable by interested clinician
- Technically accurate – backed up in Supplement & Rscript



Naomi Wray,
UQ &
UoOxford



Graham Murray,
UoCambridge



Jehannine Austin,
UoBritish Columbia





Ian Hickie,
UoSdney



John
McGrath, UQ



Tian Lin, UQ



Likely applications: Common diseases/ disorders for which there is already population screening

Likely first applications: Cancers: breast and colorectal; common eye disorders: glaucoma, macular degeneration; heart disease

PRS could have utility in community settings (stratification to better triage people into established screening programs)

Polygenic risk score applications

JAMA Psychiatry | Review

From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD; Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Goal:

- Understandable by interested clinician
- Technically accurate – backed up in Supplement & Rscript



Naomi Wray,
UQ &
UoOxford



Graham Murray,
UoCambridge



Jehannine Austin,
UoBritish Columbia



Ian Hickie,
UoSdney



John
McGrath, UQ



Tian Lin, UQ


Cohort where PRS applied:

Utility of PRS:

Likely applications:


Likely first applications:

Symptoms: help-seeking



Of 100 people presenting at clinic with symptoms but without a clear diagnosis, a higher proportion than in a population sample will go on to get "the disease" in their lifetime

PRS contribute to clinical decisions



Of 100 people presenting with symptoms AND in the top PRS stratum, a higher proportion than in the clinic-presenting cohort will go on to get diagnosis of "the disease" in their lifetime

When there is no clear diagnosis based on presenting symptoms, guide monitoring of emergent symptoms

Differentiating between type 1 and type 2 diabetes

PRS could contribute to clinical decision-making for those presenting with symptoms but where formal diagnosis is unclear.

Polygenic risk score applications

JAMA Psychiatry | Review

From Basic Science to Clinical Application of Polygenic Risk Scores A Primer

Naomi R. Wray, PhD; Tian Lin, PhD; Jehannine Austin, PhD; John J. McGrath, MD, PhD; Ian B. Hickie, MD; Graham K. Murray, MD, PhD; Peter M. Visscher, PhD

Goal:

- Understandable by interested clinician
- Technically accurate – backed up in Supplement & Rscript



Naomi Wray, UQ & UoOxford



Graham Murray, UoCambridge



Jehannine Austin, UoBritish Columbia



Ian Hickie, UoSydney



John McGrath, UQ



Tian Lin, UQ


Cohort where PRS applied:

Utility of PRS:

Likely applications:





Likely first applications:

PRS could contribute to treatment choices, but more data are needed to allow development of PRS in this context.



Justify for one disease and the rest come for free!

One disease



Methodology and challenges

Polygenic risk score methods

A weighted sum of the count of risk alleles


$$PRS = \widehat{\beta}_1 x_{i1} + \widehat{\beta}_2 x_{i2} + \widehat{\beta}_3 x_{i3} + \dots = \sum_{j=1}^{n_{SNP}} \widehat{\beta}_j x_{ij}$$

How many SNPs?
Which SNPs?
What weights?

Basic method:

Clumping & P-value thresholding (C+PT):

- Select most associated SNP in tower – LD-based clumping
- Select on a p-value threshold



Polygenic risk score methods

A weighted sum of the count of risk alleles


$$PRS = \widehat{\beta}_1 x_{i1} + \widehat{\beta}_2 x_{i2} + \widehat{\beta}_3 x_{i3} + \dots = \sum_{j=1}^{n_{SNP}} \widehat{\beta}_j x_{ij}$$

How many SNPs?
Which SNPs?
What weights?

Basic method:

Clumping & P-value thresholding (C+PT):

- Select most associated SNP in tower – LD-based clumping
- Select on a p-value threshold



Polygenic risk score methods

A weighted sum of the count of risk alleles


$$\text{PRS} = \hat{\beta}_1 x_{i1} + \hat{\beta}_2 x_{i2} + \hat{\beta}_3 x_{i3} + \dots = \sum_{j=1}^{n_{\text{SNP}}} \hat{\beta}_j x_{ij}$$

How many SNPs?
Which SNPs?
What weights?

Basic method:

Clumping & P-value thresholding (C+PT):

- Select most associated SNP in tower – LD-based clumping
- Select on a p-value threshold




A weighted sum of the count of risk alleles

$$PRS = \hat{\beta}_1 x_{i1} + \hat{\beta}_2 x_{i2} + \hat{\beta}_3 x_{i3} + \dots = \sum_{j=1}^{n_{SNP}} \hat{\beta}_j x_{ij}$$


How many SNPs?
Which SNPs?
What weights?

New methods model genetic architecture


LDpred-Inf
SBLUP




LDPred2
SBayesC



BSLMM



SBayesR



Polygenic risk score methods


Table 1. Summary of Methods Used to Generate Polygenic Scores

Method	Distribution of SNP Effects (β)	Tuning Sample	Predefined Parameters	Parameters Estimated in Tuning Sample
PC+T	None	Yes	-	p -value threshold
SBLUP	$\beta \sim N\left(0, \frac{h_g^2}{m}\right)$ h_g^2 : SNP-based heritability, m : number of SNPs; $\lambda = m(1 - h_g^2)/h_g^2$	No	λ LD radius in kb	-
LDpred2-Inf	Same as SBLUP	No	h_g^2 LD radius in cM or kb	-
LDpred-funct	$\beta_j \sim N(0, c\sigma_j^2)$ $\sum_{j=1}^M 1_{\sigma_j^2 > 0} c\sigma_j^2 = h_g^2$, c is a normalizing constant, σ_j^2 is the expected per SNP heritability under the baseline-LD annotation model estimated by stratified LDSC from the discovery GWAS within LDpred-funct software	No	h_g^2 LD radius in number of SNPs	-
LDpred2	$\beta_j \sim \begin{cases} N\left(0, \frac{h_g^2}{\pi m}\right), & \text{with probability of } \pi \\ 0, & \text{with probability of } 1 - \pi \end{cases}$ When sparsity is "true," the β_j for SNPs in the $(1 - \pi)$ partition are all set to zero	Yes	h_g^2 π software default values, LD radius in cM or kb	π , sparsity
Lassosum	$f(\beta) = \mathbf{y}^T \mathbf{y} + (1 - s) \beta^T \mathbf{X}^T \mathbf{X} \beta - 2 \beta^T \mathbf{X}^T \mathbf{y} + s \beta^T \beta + 2 \lambda \ \beta\ _1$ \mathbf{X} : $n \times m$ matrix of genotypes of LD reference sample, where n is sample size	Yes	LD blocks	λ , s
PRS-CS	$\beta_j \sim N\left(0, \frac{\sigma_j^2}{n} \psi_j\right)$ $\psi_j \sim G(a, \delta_j)$ $\delta_j \sim G(b, \phi)$, ϕ is a global scaling parameter	Yes	$a = 1, b = 0.5$ n LD blocks	ϕ
PRS-CS-auto	Same as PRS-CS, but estimates ϕ from the discovery GWAS	No	$a = 1, b = 0.5$ n LD blocks	-
SBayesR	$\beta_j \pi, \sigma_j^2 \sim \begin{cases} 0, & \text{with probability of } \pi_1 \\ N(0, \gamma_2 \sigma_j^2), & \text{with probability of } \pi_2 \\ \vdots \\ N(0, \gamma_c \sigma_j^2), & \text{with probability of } 1 - \sum_{c=1}^{C-1} \pi_c \end{cases}$ $\sigma_j^2 \sim \text{Inv} - \chi^2$ (d.f. = 4) $\pi_i \sim \text{Dir}(1)$, estimated from discovery GWAS in SBayesR software γ_i are scaling parameters	No	LD radius in cM or kb $C = 4$ γ software default values	-
MegaPRS	Lasso: $\beta_j \sim DE(\lambda/\sigma_j)$ Ridge regression: $\beta_j \sim N(0, v\sigma_j^2)$ BOLT-LMM: $\beta_j \sim \begin{cases} N\left(0, \frac{(1-f_2)\sigma_j^2}{\pi}\right), & \text{with probability of } \pi \\ N\left(0, \frac{f_2\sigma_j^2}{1-\pi}\right), & \text{with probability of } 1 - \pi \end{cases}$ f_2 is the proportion of the total mixture variance in the second normal distribution BayesR: similar to SBayesR with $C = 4$, and π_i and γ_i estimated in the tuning sample σ_j^2 is the expected per SNP-heritability under BLD-LDAK model using SumHer	Yes	LD radius in cM or kb Parameters used in BLD-LDAK Grid search parameter values for each method	The tuning cohort is used to estimate the parameters that maximize prediction for each model, and from these the model that maximizes prediction is selected

Archival Report


A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts

Guiyan Ni, Jian Zeng, Joana A. Revez, Ying Wang, Zhili Zheng, Tian Ge, Restuadi Restuadi, Jacqueline Kiewa, Dale R. Nyholt, Jonathan R.I. Coleman, Jordan W. Smoller, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Jian Yang, Peter M. Visscher, and Naomi R. Wray




- Random effects models > fixed effects models
- Mixture models > non-mixture (infinitesimal) models

Crohn's Disease
 r_g EUR-ASN 0.76



Ulcerative Colitis
 r_g EUR-ASN 0.79



European

Asian

European

Asian

Monomorphic in non-Europeans Similar MAF and OR Different MAF Different OR Different MAF and different OR


Issues

- Same causal variants
 - Different allele frequencies
 - LD differences
 - Different effect sizes
- Different causal variants
 - GxE
 - Different phenotype

In general:

We expect common causal variants to be shared across ancestries

But correlation structure differs




PERSPECTIVE

<https://doi.org/10.1038/s41588-019-0379-x>


nature
genetics

Clinical use of current polygenic risk scores may exacerbate health disparities



Alicia R. Martin ^{1,2,3*}, Masahiro Kanai ^{1,2,3,4,5}, Yoichiro Kamatani ^{1,5,6}, Yukinori Okada ^{1,5,7,8}, Benjamin M. Neale ^{1,2,3} and Mark J. Daly ^{1,2,3,9}



Predicted into Japanese




Predicted into European



Trans-ancestry prediction


Use GWAS data from UK Biobank (UKB) European samples and Biobank Japan East Asian (EAS) samples to predict UKB EAS


nature genetics 

Article <https://doi.org/10.1038/s41588-024-01704-y>

Leveraging functional genomic annotations and genome coverage to improve polygenic prediction of complex traits within and between ancestries

Received: 1 October 2022 Zhili Zheng^{1,2,3}, Shouye Liu¹, Julia Sidorenko¹, Ying Wang¹, Tian Lin¹,
 Accepted: 5 March 2024 Loic Yengo¹, Patrick Turley^{1,4}, Alireza An^{1,5}, Ruijia Wang¹,
 Published online: 30 April 2024 Ijia M. Nolte⁶, Harold Snieder¹, LifeLines Cohort Study⁷, Jian Yang^{1,8,9},
 & Jian Zeng^{1,10}, Michael E. Goddard^{11,12}, Peter M. Visscher^{1,13}

 Check for updates



PGS are ...

- Imperfect genetic predictors with inherently limited accuracy.
- Being evaluated in clinical settings and are often combined with other predictive measures to predict the total disease risk.
- Useful in risk stratification to better triage people into established screening programs.
- Available for an individual for all common diseases from birth.
- being improved with more data and better methods, especially for its utility across ancestries.

PGS are not ...

- Not diagnostic.
- Not absolute risk and do not provide a baseline or timeframe for the progression of a disease.
- Not and never will be stand-alone predictors of common diseases.
- PGS accuracy will increase with GWAS sample size but are never going to be able to definitively predict complex conditions.

Practical 1: Computation of PRS using C+PT

https://cnsgenomics.com/data/teaching/GNGWS24/module5/Practical1_PRS.html

To log into your server, type command below in **Terminal** for Mac/Linux users or in **Command Prompt** or **PowerShell** for Windows users.

```
ssh username@hostname
```

And then key in the provided password.